Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. BAX
BAX logo

BAX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Baxter International Inc (BAX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
18.050
1 Day change
3.38%
52 Week Range
35.770
Analysis Updated At
2026/03/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Baxter International Inc (BAX) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment at this time. The stock is in a bearish trend with no significant positive catalysts, weak financial performance, and neutral trading sentiment. Analysts have lowered price targets, and there are no recent signals from Intellectia Proprietary Trading Signals to suggest a strong buy opportunity.

Technical Analysis

The stock is in a bearish trend with MACD negatively expanding (-0.31), RSI at 20.911 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is near a key support level (S1: 18.812), but the overall trend remains negative.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high Option Volume Put-Call Ratio (1.7) indicates bearish sentiment, while the Open Interest Put-Call Ratio (0.45) suggests more interest in calls than puts. However, the overall sentiment leans negative.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
5

Positive Catalysts

  • NULL identified. There is no recent news or significant insider or hedge fund activity to act as a positive catalyst.

Neutral/Negative Catalysts

  • Analysts have consistently lowered price targets, citing weak financial performance, margin pressures, and underwhelming 2026 guidance. The company's gross margin dropped significantly (-45.16% YoY), and net income remains negative.

Financial Performance

In Q4 2025, revenue increased 8.03% YoY to $2.97B, but net income was -$1.13B, up 120.31% YoY. EPS improved to -2.2, but gross margin fell to 20.24%, down 45.16% YoY. The financials indicate growth in revenue but significant profitability challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have a neutral to bearish stance on the stock. Multiple firms, including Goldman Sachs, UBS, and Deutsche Bank, have lowered price targets, citing weak financial performance and limited near-term visibility. The average price target is below the current price, reflecting a lack of confidence in the stock's upside potential.

Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
Wall Street analysts forecast BAX stock price to rise
2 Buy
5 Hold
1 Sell
Hold
Current: 17.460
sliders
Low
15
Averages
22.13
High
30
Current: 17.460
sliders
Low
15
Averages
22.13
High
30
Citi
Neutral
downgrade
$21 -> $19
AI Analysis
2026-03-11
New
Reason
Citi
Price Target
$21 -> $19
AI Analysis
2026-03-11
New
downgrade
Neutral
Reason
Citi lowered the firm's price target on Baxter to $19 from $21 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain "healthy" despite the recent volatility, the analyst tells investors in a research note. Citi's top picks are iRhythm and Medtronic.
Goldman Sachs
Neutral
downgrade
$21 -> $17
2026-02-17
Reason
Goldman Sachs
Price Target
$21 -> $17
2026-02-17
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Baxter to $17 from $21 and keeps a Neutral rating on the shares. The company's results and 2026 outlook generally fell short of estimates as margin pressures and higher non-operating items drove 2026 EPS guidance mid-point 16% below pre-Q4 consensus, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BAX
Unlock Now

People Also Watch